[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 8 of about 8
1. Gras Cabrerizo JR, Orús Dotú C, Montserrat Gili JR, Fabra Llopis JM, León Vintro X, De Juan Beltrán J: [Epidemiologic analysis of 72 carcinomas of the nasal cavity and paranasal sinuses]. Acta Otorrinolaringol Esp; 2006 Oct;57(8):359-63
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epidemiologic analysis of 72 carcinomas of the nasal cavity and paranasal sinuses].
  • [Transliterated title] Análisis epidemiológico de 72 carcinomas de fosas y senos paranasales.
  • OBJECTIVE: The aim of this study is to define the epidemiological aspects of carcinoma of the nasal cavity and paranasal sinuses.
  • MATERIAL AND METHODS: We performed a retrospective study of 72 carcinomas of the nasal cavity and paranasal sinuses.
  • Various sites, age and sex distribution, drug consumption, TNM stage grouping and treatment were reported.
  • The site of origin was paranasal sinuses in 46 patients (64%), 30 in ethmoid sinus, 15 in maxillary sinus and 1 in sphenoid sinus.
  • Squamous cell carcinoma was the most frequent histological type in both localizations.
  • The 5-year adjusted survival rate for all patients was 60% (IC: 54-66), 36% (IC: 28-44) for paranasal sinus carcinoma and 86% (IC: 79-93) for nasal cavity carcinoma.
  • The 5-year adjusted survival rate according to the T distribution in 46 carcinomas paranasal sinus was 80% T2, 71% T3, 19% T4a and 6% T4b.(p = 0.0002).
  • CONCLUSIONS: Carcinoma of nasal cavity and paranasal sinuses represent a group of tumors that differ from the rest of carcinomas of the head and neck.
  • [MeSH-major] Nasal Cavity. Nose Neoplasms / epidemiology. Paranasal Sinus Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17117693.001).
  • [ISSN] 0001-6519
  • [Journal-full-title] Acta otorrinolaringológica española
  • [ISO-abbreviation] Acta Otorrinolaringol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


2. Papadimitrakopoulou VA, Ginsberg LE, Garden AS, Kies MS, Glisson BS, Diaz EM Jr, Clayman G, Morrison WH, Liu DD, Blumenschein G Jr, Lippman SM, Schommer D, Gillenwater A, Goepfert H, Hong WK: Intraarterial cisplatin with intravenous paclitaxel and ifosfamide as an organ-preservation approach in patients with paranasal sinus carcinoma. Cancer; 2003 Nov 15;98(10):2214-23
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraarterial cisplatin with intravenous paclitaxel and ifosfamide as an organ-preservation approach in patients with paranasal sinus carcinoma.
  • BACKGROUND: The objectives of this study were to determine the efficacy, organ-preservation rate, and safety of intraarterial (IA) cisplatin in combination with intravenous paclitaxel and ifosfamide in patients with locally advanced carcinoma of the paranasal sinuses who required orbital exenteration or major craniofacial resection for complete tumor resection.
  • Alternative approaches, including the integration of targeted therapy agents in induction chemotherapy regimens followed by concomitant chemotherapy and RT or eye-sparing surgery, need further exploration.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / drug therapy. Paranasal Sinus Neoplasms / drug therapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 American Cancer Society.
  • (PMID = 14601092.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


3. Dulguerov P, Allal AS: Nasal and paranasal sinus carcinoma: how can we continue to make progress? Curr Opin Otolaryngol Head Neck Surg; 2006 Apr;14(2):67-72
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nasal and paranasal sinus carcinoma: how can we continue to make progress?
  • PURPOSE OF REVIEW: New developments in the nasal and paranasal sinus cancers are reviewed.
  • RECENT FINDINGS: In addition to woodworking, several risk factors for nasal and paranasal sinus cancers have been identified, most notably smoking.
  • Progress in the differential diagnosis of small round cell nasal and paranasal sinus cancers allows the precise diagnosis of esthesioneuroblastoma.
  • Major developments include endoscopic resection of nasal and paranasal sinus cancers, high-precision radiotherapy techniques such as intensity-modulated radiotherapy, and proton-beam radiotherapy.
  • Although chemotherapy is important for aggressive neoplasms, its generalized use for nasal and paranasal sinus cancers awaits the application/development of newer drugs.
  • These drugs might be applied locally since the majority of recurrences remain local.
  • SUMMARY: Progress in the treatment of nasal and paranasal sinus cancers could be achieved through better prevention and the developments of more selective treatments such as endoscopic resection, high-precision radiotherapy, and new chemotherapy drugs.
  • [MeSH-major] Carcinoma. Nasal Cavity / pathology. Nose Neoplasms. Paranasal Sinus Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16552261.001).
  • [ISSN] 1068-9508
  • [Journal-full-title] Current opinion in otolaryngology & head and neck surgery
  • [ISO-abbreviation] Curr Opin Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 61
  •  go-up   go-down


Advertisement
4. Padovani L, Pommier P, Clippe S S, Martel-Lafay I, Malet C, Poupart M, Zrounba P, Ceruse P, Desmes S, Carrie C, Montbarbon X, Ginestet C: Three-dimensional conformal radiotherapy for paranasal sinus carcinoma: clinical results for 25 patients. Int J Radiat Oncol Biol Phys; 2003 May 1;56(1):169-76
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three-dimensional conformal radiotherapy for paranasal sinus carcinoma: clinical results for 25 patients.
  • PURPOSE: To assess local control, survival, and clinical and dosimetric prognostic factors in 25 patients with locally advanced maxillary or ethmoid sinus carcinoma treated by three-dimensional conformal radiotherapy (RT).
  • RESULTS: The median radiation dose to the planned treatment volume was 63 Gy, with a minimal dose of 60 Gy, except in 2 patients whose cancer progressed during RT.
  • CONCLUSIONS: Improving local control remains the main challenge in RT for paranasal tumors.
  • [MeSH-major] Carcinoma / radiotherapy. Imaging, Three-Dimensional. Paranasal Sinus Neoplasms / radiotherapy. Radiotherapy Planning, Computer-Assisted / methods. Radiotherapy, Conformal / methods
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Disease Progression. Disease-Free Survival. Dose-Response Relationship, Radiation. Ethmoid Sinus. Eye Injuries / etiology. Eye Injuries / prevention & control. Female. Follow-Up Studies. Humans. Life Tables. Male. Maxillary Sinus Neoplasms / drug therapy. Maxillary Sinus Neoplasms / mortality. Maxillary Sinus Neoplasms / radiotherapy. Maxillary Sinus Neoplasms / surgery. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Optic Nerve Injuries / etiology. Optic Nerve Injuries / prevention & control. Radiation Injuries / etiology. Radiation Injuries / prevention & control. Radiotherapy Dosage. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12694835.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Yokoyama J: [Usefulness of CT-angiography for superselective intra-arterial chemotherapy for advanced head and neck cancers]. Gan To Kagaku Ryoho; 2002 Nov;29(12):2302-6
Hazardous Substances Data Bank. SODIUM THIOSULFATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Usefulness of CT-angiography for superselective intra-arterial chemotherapy for advanced head and neck cancers].
  • Eighteen N3 cases, fourteen skullbase invasion cases and twenty-six cases of paranasal sinus cancer with orbital invasion were treated by superselective intra-arterial chemotherapy using CDDP and sodium thiosulfate to preserve the organs and to improve poor prognosis.
  • CT-arteriography (CTA) was used to diagnosis all feeding arteries of advanced cancers before infusing CDDP.
  • In skullbase invasion cases, the number of complete responses (CR) was 8/14, and that of partial responses (PR) was 6/14.
  • CTA is a very efficient method for diagnosing all feeding arteries of advanced cancers in the superselective intra-arterial chemotherapy.
  • [MeSH-major] Angiography. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiography. Infusions, Intra-Arterial / methods. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cisplatin / administration & dosage. Female. Humans. Male. Middle Aged. Orbital Neoplasms. Paranasal Sinus Neoplasms / drug therapy. Skull Base Neoplasms / drug therapy. Thiosulfates / administration & dosage

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12484060.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Thiosulfates; HX1032V43M / sodium thiosulfate; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


6. Lalami Y, Vereecken P, Dequanter D, Lothaire P, Awada A: Salivary gland carcinomas, paranasal sinus cancers and melanoma of the head and neck: an update about rare but challenging tumors. Curr Opin Oncol; 2006 May;18(3):258-65
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salivary gland carcinomas, paranasal sinus cancers and melanoma of the head and neck: an update about rare but challenging tumors.
  • PURPOSE OF REVIEW: This is a review about recent clinical developments in rare cancers of the head and neck.
  • SUMMARY: As salivary gland carcinomas, paranasal sinus cancers and melanoma of the head and neck are rare malignancies, these tumors must be treated in specialized anticancer centers with access to the latest surgical and irradiation techniques.
  • [MeSH-major] Carcinoma / therapy. Head and Neck Neoplasms / therapy. Melanoma / therapy. Paranasal Sinus Neoplasms / therapy. Salivary Gland Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Blindness / etiology. Clinical Trials as Topic. Combined Modality Therapy. Drug Delivery Systems. Drugs, Investigational / therapeutic use. Humans. Lymphatic Metastasis. Multicenter Studies as Topic. Neoadjuvant Therapy. Palliative Care. Radiation Injuries / etiology. Radiotherapy / adverse effects. Radiotherapy / methods. Radiotherapy, Adjuvant. Sentinel Lymph Node Biopsy

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16552238.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Drugs, Investigational
  • [Number-of-references] 85
  •  go-up   go-down


7. Huang D, Xia P, Akazawa P, Akazawa C, Quivey JM, Verhey LJ, Kaplan M, Lee N: Comparison of treatment plans using intensity-modulated radiotherapy and three-dimensional conformal radiotherapy for paranasal sinus carcinoma. Int J Radiat Oncol Biol Phys; 2003 May 1;56(1):158-68
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of treatment plans using intensity-modulated radiotherapy and three-dimensional conformal radiotherapy for paranasal sinus carcinoma.
  • PURPOSE: To compare intensity-modulated radiotherapy (IMRT) treatment planning with three-dimensional conformal radiotherapy (3D-CRT) planning for paranasal sinus carcinoma.
  • MATERIALS AND METHODS: Treatment plans using traditional 3-field technique, 3D-CRT planning, and inverse planning IMRT were developed for a case of paranasal sinus cancer requiring adjuvant radiotherapy.
  • Inverse planning IMRT provided the best treatment for all paranasal sinus carcinomas, but required stringent immobilization criteria.
  • [MeSH-major] Carcinoma / radiotherapy. Imaging, Three-Dimensional. Paranasal Sinus Neoplasms / radiotherapy. Radiotherapy Planning, Computer-Assisted / methods. Radiotherapy, Adjuvant / methods. Radiotherapy, Conformal / methods
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Brain Stem / injuries. Brain Stem / radiation effects. Chemotherapy, Adjuvant. Combined Modality Therapy. Dose-Response Relationship, Radiation. Eye Injuries / etiology. Eye Injuries / prevention & control. Female. Humans. Immobilization. Masks. Maxillary Sinus Neoplasms / drug therapy. Maxillary Sinus Neoplasms / radiotherapy. Maxillary Sinus Neoplasms / surgery. Optic Chiasm / radiation effects. Optic Nerve Injuries / etiology. Optic Nerve Injuries / prevention & control. Radiation Injuries / etiology. Radiation Injuries / prevention & control. Radiotherapy Dosage

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12694834.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


8. Myers LL, Oxford LE: Differential diagnosis and treatment options in paranasal sinus cancers. Surg Oncol Clin N Am; 2004 Jan;13(1):167-86
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential diagnosis and treatment options in paranasal sinus cancers.
  • Paranasal sinus malignancies are challenging to treat.
  • Given the low incidence and diverse pathologies of paranasal sinus cancers, it is extremely difficult to perform prospective, randomized clinical trials to compare different treatment approaches.
  • Improving the prognosis of these cancers continues to be a difficult task, even in light of advances in surgical techniques,radiation delivery techniques, and new chemotherapeutic agents.
  • Aggressive and oncologically sound surgical resection combined with radiation therapy remains the treatment of choice for most patients.Finally, advances in the diagnosis and staging by use of molecular or DNA markers of tumor behavior may allow for more directed therapy.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / therapy. Paranasal Sinus Neoplasms / diagnosis. Paranasal Sinus Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / therapy. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Adenoid Cystic / therapy. Combined Modality Therapy. Craniotomy. Diagnosis, Differential. Esthesioneuroblastoma, Olfactory / pathology. Esthesioneuroblastoma, Olfactory / therapy. Humans. Lymphoma / therapy. Melanoma / diagnosis. Melanoma / mortality. Melanoma / therapy. Neoplasm Staging. Paranasal Sinuses / anatomy & histology. Prognosis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15062368.001).
  • [ISSN] 1055-3207
  • [Journal-full-title] Surgical oncology clinics of North America
  • [ISO-abbreviation] Surg. Oncol. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 87
  •  go-up   go-down






Advertisement